Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a ...

The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool's ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...